Most recent studies confirmed the increase in chemotherapy activity within the synergy of CD200 (or CD200R) blockade to cure and to produce immune resistance to metastasis of metastatic breast cancer in mice models [11]. The gene discussed is CD200; the disease is breast carcinoma.